Literature DB >> 17962889

[Complete resection of endobronchial hamartomas via bronchoscopic techniques, electrosurgery by Argon plasma and laser].

Diva Ferreira1, José Almeida, Bárbara Parente, João Moura E Sá.   

Abstract

Hamartomas are benign neoplasms often located in lung and frequently asymptomatic. They are typically discovered incidentally with thorax radiographic stu- dies. About 1.4-20% of hamartomas have endobronchial location and can be symptomatic due to airway obstruction. Traditionally, surgical resection has been considered the standard of care for endobronchial hamartoma. However, there is increasing experience using endoscopic treatment and a paucity of reported complications. Endoscopic resection has comparable therapeutic efficacy with surgical resection but spares a major operation. We report two cases of endobronchial hamartomas, each diagnosed and definitively treated with bronchoscopic techniques. Persistent symptoms and abnormal radiological features were the impetus for initial diagnostic bronchoscopy. Endobronchial treatment was performed using electrosurgery by Argon plasma (APC) and Nd:YAG la- ser. This approach resulted in complete resolution of both patients' symptoms. Follow-up bronchoscopic examinations excluded residual or recurrent disease.

Entities:  

Mesh:

Year:  2007        PMID: 17962889

Source DB:  PubMed          Journal:  Rev Port Pneumol        ISSN: 0873-2159


  2 in total

1.  Endobronchial lipomatous hamartoma: an incidental finding in a patient with atrial fibrillation-a case report.

Authors:  Friederike Schneider; Hauke Winter; Florian Schwarz; Manuel Niederhagen; Vivian Arias-Herrera; Eimo Martens; Stefan Kääb; Hans Theiss
Journal:  Case Rep Med       Date:  2012-02-02

2.  Patient-related independent clinical risk factors for early complications following Nd: YAG laser resection of lung cancer.

Authors:  Branislav Perin; Bojan Zaric; Svetlana Jovanovic; Jovan Matijasevic; Jelena Stanic; Ivan Kopitovic; Biljana Zvezdin; Milan Antonic
Journal:  Ann Thorac Med       Date:  2012-10       Impact factor: 2.219

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.